SG10201707002VA - Biheteroaryl compounds and uses thereof - Google Patents

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Zoology (AREA)
Immunology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)

SG10201707002VA2013-05-012014-04-30Biheteroaryl compounds and uses thereofSG10201707002VA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361817966P	2013-05-01	2013-05-01

Publications (1)

Publication Number	Publication Date
SG10201707002VAtrue SG10201707002VA (en)	2017-10-30

Family

ID=51841525

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201707002VASG10201707002VA (en)	2013-05-01	2014-04-30	Biheteroaryl compounds and uses thereof
SG11201509027WASG11201509027WA (en)	2013-05-01	2014-04-30	Biheteroaryl compounds and uses thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201509027WASG11201509027WA (en)	2013-05-01	2014-04-30	Biheteroaryl compounds and uses thereof

Country Status (22)

Country	Link
US (8)	US9266862B2 (en)
EP (1)	EP2991978B1 (en)
JP (4)	JP6229042B2 (en)
KR (2)	KR101836431B1 (en)
CN (2)	CN105431420B (en)
AR (1)	AR096151A1 (en)
AU (2)	AU2014261894C1 (en)
BR (1)	BR112015027055B1 (en)
CA (1)	CA2911051C (en)
CL (1)	CL2015003147A1 (en)
CR (2)	CR20200177A (en)
EA (3)	EA029568B8 (en)
IL (2)	IL296526B2 (en)
MA (3)	MA42164B1 (en)
MX (1)	MX2015015130A (en)
MY (1)	MY182082A (en)
PE (2)	PE20161063A1 (en)
PH (2)	PH12019502378A1 (en)
SG (2)	SG10201707002VA (en)
TW (3)	TW201800403A (en)
UA (1)	UA121016C2 (en)
WO (1)	WO2014177060A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112014026952B1 (en)*	2012-05-03	2022-03-15	Genentech, Inc	Pyrazole aminopyrimidine derivatives and composition comprising them
CA2896187A1 (en)	2013-01-18	2014-07-24	F. Hoffmann-La Roche Ag	3-substituted pyrazoles and use as dlk inhibitors
WO2014177524A1 (en)*	2013-05-01	2014-11-06	F. Hoffmann-La Roche Ag	C-linked heterocycloalkyl substituted pyrimidines and their uses
SG10201707002VA (en)*	2013-05-01	2017-10-30	Hoffmann La Roche	Biheteroaryl compounds and uses thereof
MX2016008110A (en)*	2013-12-20	2016-08-19	Hoffmann La Roche	Pyrazole derivatives and uses thereof as inhibitors of dlk.
CN104926716A (en)*	2015-06-10	2015-09-23	哈尔滨工业大学	Pyridine derivative 2,6-di[(6-methoxy pyridine-2-yl)methyl] pyridine and synthesis method thereof
US20180057507A1 (en)*	2016-08-29	2018-03-01	Board Of Regents, The University Of Texas System	Inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
CA3045947A1 (en)	2016-12-08	2018-06-14	Michael J. Soth	Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
CN119613408A (en)	2017-07-14	2025-03-14	豪夫迈·罗氏有限公司	Bicyclic ketone compounds and methods of use thereof
MA50356A (en)	2017-10-11	2021-04-21	Hoffmann La Roche	BICYCLIC COMPOUNDS INTENDED FOR USE AS KINASE RIP1 INHIBITORS
US11180480B2 (en)*	2017-10-17	2021-11-23	Sensorion	Synthesis of 4-aminopyrimidine compounds
WO2019086494A1 (en)	2017-10-31	2019-05-09	F. Hoffmann-La Roche Ag	Bicyclic sulfones and sulfoxides and methods of use thereof
CN112074519B (en)	2018-04-20	2024-08-02	豪夫迈·罗氏有限公司	Compounds useful as inhibitors of RIP1 kinase for the treatment of, for example, irritable Bowel Syndrome (IBS)
CN113226466A (en)	2018-10-22	2021-08-06	科登特治疗公司	Crystalline forms of potassium channel modulators
US12083114B2 (en)	2018-12-19	2024-09-10	Disarm Therapeutics, Inc.	Inhibitors of SARM1 in combination with neuro-protective agents
CN113302193A (en)	2019-01-11	2021-08-24	豪夫迈·罗氏有限公司	Bicyclic pyrrolotriazolone compounds and methods of use thereof
KR20210123337A (en)*	2019-01-31	2021-10-13	더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드	Aromatic ring or heteroaromatic ring compound, preparation method thereof and medical use thereof
US11560366B2 (en)	2019-10-21	2023-01-24	Board Of Regents, The University Of Texas System	Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
JP2021070684A (en)*	2019-10-30	2021-05-06	東ソー株式会社	Method of producing halogen compound
IL295088A (en)	2020-01-29	2022-09-01	Kamari Pharma Ltd	Compounds and preparations for use in the treatment of skin disorders
BR112023005853A2 (en)*	2020-10-02	2023-05-02	Genentech Inc	PROCESS FOR PREPARING A COMPOUND OF FORMULA I, COMPOUNDS, PROCESSES FOR PREPARING COMPOUND 1, CRYSTALLINE FORM, PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARING THE CRYSTALLINE FORM OF COMPOUND I AND METHOD FOR TREATMENT OF A NEURODEGENERATIVE CONDITION
US20250032489A1 (en)*	2021-09-01	2025-01-30	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Mixed lineage kinase inhibitors and methods of use
WO2023067550A1 (en)*	2021-10-20	2023-04-27	Yousef Najajreh	Allosteric inhibitor compounds for overcoming cancer resistance
TW202435863A (en)	2023-01-28	2024-09-16	芬蘭商奧利安公司	Cbl-b inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (en)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipids and surfactants in an aqueous medium
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en)	1990-04-23	1993-12-07	Alkermes, Inc.	Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en)	1990-04-23	1992-05-12	Alkermes, Inc.	Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE191853T1 (en)	1992-07-27	2000-05-15	Us Health	TARGETING LIPOSOMES FOR THE BLOOD-BRAIN BARRIER
US6514221B2 (en)	2000-07-27	2003-02-04	Brigham And Women's Hospital, Inc.	Blood-brain barrier opening
US20020065259A1 (en)	2000-08-30	2002-05-30	Schatzberg Alan F.	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en)	2000-10-30	2006-04-25	Pain Therapeutics, Inc.	Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (en)	2001-05-05	2008-01-24	Lts Lohmann Therapie-Systeme Ag	Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation
US20030129186A1 (en)	2001-07-25	2003-07-10	Biomarin Pharmaceutical Inc.	Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en)	2002-02-27	2003-08-28	Schatzberg Alan F.	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
NZ539062A (en)	2002-09-30	2007-05-31	Bayer Pharmaceuticals Corp	Fused azole-pyrimidine derivatives exhibiting enhanced potency for phosphotidylinositol-3-kinase (P13K) inhibition
EP1581186A2 (en)	2002-12-03	2005-10-05	Blanchette Rockefeller Neurosciences Institute	Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
JP2007505142A (en)	2003-09-10	2007-03-08	セダーズ−シナイメディカルセンター	Potassium channel-mediated delivery of drugs across the blood brain barrier
GB0508471D0 (en)	2005-04-26	2005-06-01	Celltech R&D Ltd	Therapeutic agents
JO2660B1 (en)*	2006-01-20	2012-06-17	نوفارتيس ايه جي	PI-3 Kinase inhibitors and methods of their use
WO2008064244A2 (en)	2006-11-20	2008-05-29	The Trustees Of Columbia University In The City Of New York	Phosphoinositide modulation for the treatment of neurodegenerative diseases
US8173647B2 (en)	2007-02-06	2012-05-08	Gordana Atallah	PI 3-kinase inhibitors and methods of their use
NZ582708A (en)	2007-07-19	2012-04-27	Schering Corp	Heterocyclic amide compounds as protein kinase inhibitors
WO2009066084A1 (en)*	2007-11-21	2009-05-28	F. Hoffmann-La Roche Ag	2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
US20100056609A1 (en)	2008-08-26	2010-03-04	Washington University	Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
KR20110090911A (en)*	2008-10-31	2011-08-10	노파르티스 아게	Combination of phosphatidylinositol-3-kinase (PI3) inhibitors and MTOR inhibitors
GB2465405A (en)	2008-11-10	2010-05-19	Univ Basel	Triazine, pyrimidine and pyridine analogues and their use in therapy
BR112012008385A2 (en)	2009-09-09	2019-09-24	Avila Therapeutics Inc	p13 kinase inhibitors and their use.
EP3011970A3 (en)	2009-10-22	2016-06-08	F. Hoffmann-La Roche AG	Modulation of axon degeneration
GB201004200D0 (en)*	2010-03-15	2010-04-28	Univ Basel	Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
NZ603644A (en)	2010-05-24	2014-10-31	Univ Rochester	Bicyclic heteroaryl kinase inhibitors and methods of use
AU2012225382B2 (en)*	2011-03-09	2016-10-27	Celgene Avilomics Research, Inc.	PI3 kinase inhibitors and uses thereof
SG10201707002VA (en)	2013-05-01	2017-10-30	Hoffmann La Roche	Biheteroaryl compounds and uses thereof
CN103483345B (en)	2013-09-25	2016-07-06	中山大学	PI3K inhibitors of kinases, the pharmaceutical composition comprising it and application thereof
JP5920747B1 (en)	2015-04-07	2016-05-18	エイピーエス．エスエイ	Application programs and cards

2014
- 2014-04-30SGSG10201707002VApatent/SG10201707002VA/enunknown
- 2014-04-30ARARP140101782Apatent/AR096151A1/enactiveIP Right Grant
- 2014-04-30EAEA201592060Apatent/EA029568B8/ennot_activeIP Right Cessation
- 2014-04-30MAMA42164Apatent/MA42164B1/enunknown
- 2014-04-30PHPH1/2019/502378Apatent/PH12019502378A1/enunknown
- 2014-04-30CACA2911051Apatent/CA2911051C/enactiveActive
- 2014-04-30ILIL296526Apatent/IL296526B2/enunknown
- 2014-04-30KRKR1020157034239Apatent/KR101836431B1/enactiveActive
- 2014-04-30CNCN201480024257.9Apatent/CN105431420B/enactiveActive
- 2014-04-30TWTW106110366Apatent/TW201800403A/enunknown
- 2014-04-30PEPE2016000335Apatent/PE20161063A1/enunknown
- 2014-04-30TWTW107105054Apatent/TWI710558B/enactive
- 2014-04-30PHPH1/2015/502410Apatent/PH12015502410B1/enunknown
- 2014-04-30MXMX2015015130Apatent/MX2015015130A/enunknown
- 2014-04-30BRBR112015027055-7Apatent/BR112015027055B1/enactiveIP Right Grant
- 2014-04-30MAMA38624Apatent/MA38624A1/enunknown
- 2014-04-30CRCR20200177Apatent/CR20200177A/enunknown
- 2014-04-30MYMYPI2015002684Apatent/MY182082A/enunknown
- 2014-04-30EAEA201792471Apatent/EA033084B1/ennot_activeIP Right Cessation
- 2014-04-30TWTW103115649Apatent/TWI622587B/enactive
- 2014-04-30EPEP14791795.9Apatent/EP2991978B1/enactiveActive
- 2014-04-30EAEA201991064Apatent/EA038235B1/enunknown
- 2014-04-30JPJP2016510926Apatent/JP6229042B2/enactiveActive
- 2014-04-30WOPCT/CN2014/076654patent/WO2014177060A1/enactiveIP Right Grant
- 2014-04-30SGSG11201509027WApatent/SG11201509027WA/enunknown
- 2014-04-30CNCN201910136846.0Apatent/CN110003178B/enactiveActive
- 2014-04-30KRKR1020187006149Apatent/KR102002265B1/enactiveActive
- 2014-04-30MAMA48577Apatent/MA48577A1/enunknown
- 2014-04-30PEPE2019002479Apatent/PE20200447A1/enunknown
- 2014-04-30AUAU2014261894Apatent/AU2014261894C1/enactiveActive
- 2014-04-30UAUAA201511803Apatent/UA121016C2/enunknown
- 2014-05-01USUS14/267,011patent/US9266862B2/enactiveActive
2015
- 2015-10-19ILIL242164Apatent/IL242164B/enactiveIP Right Grant
- 2015-10-23CRCR20150589Apatent/CR20150589A/enunknown
- 2015-10-26CLCL2015003147Apatent/CL2015003147A1/enunknown
- 2015-10-29USUS14/927,267patent/US10010549B2/enactiveActive
2016
- 2016-02-11USUS15/041,375patent/US10028954B2/enactiveActive
2017
- 2017-10-16JPJP2017200127Apatent/JP6655052B2/enactiveActive
- 2017-12-22USUS15/852,235patent/US20180117044A1/ennot_activeAbandoned
2018
- 2018-01-11USUS15/868,301patent/US20180133219A1/ennot_activeAbandoned
- 2018-02-22USUS15/902,746patent/USRE47848E1/enactiveActive
2019
- 2019-01-15AUAU2019200249Apatent/AU2019200249B2/enactiveActive
- 2019-09-11USUS16/568,130patent/US20200171029A1/ennot_activeAbandoned
- 2019-10-28USUS16/666,273patent/US11129832B2/enactiveActive
2020
- 2020-01-31JPJP2020014468Apatent/JP2020079264A/enactivePending
2022
- 2022-10-28JPJP2022173436Apatent/JP2023011775A/enactivePending

Also Published As

Publication number	Publication date
AU2019200249B2 (en)	2020-10-15
NZ712934A (en)	2020-10-30
CN105431420A (en)	2016-03-23
AR096151A1 (en)	2015-12-09
EA201991064A1 (en)	2020-02-28
PE20200447A1 (en)	2020-02-28
BR112015027055B1 (en)	2023-09-26
EP2991978B1 (en)	2025-08-20
BR112015027055A8 (en)	2020-01-14
US20160052940A1 (en)	2016-02-25
TW201800403A (en)	2018-01-01
PH12015502410B1 (en)	2023-05-24
JP2023011775A (en)	2023-01-24
NZ750661A (en)	2020-11-27
EA201792471A1 (en)	2018-04-30
TWI622587B (en)	2018-05-01
EA038235B1 (en)	2021-07-28
IL242164B (en)	2021-04-29
MA48577A1 (en)	2021-03-31
AU2014261894C1 (en)	2019-07-11
JP2016518383A (en)	2016-06-23
CA2911051C (en)	2021-08-17
EA201592060A1 (en)	2016-02-29
CL2015003147A1 (en)	2016-06-17
TW201506018A (en)	2015-02-16
US10028954B2 (en)	2018-07-24
MA42164A1 (en)	2019-01-31
MA42164B1 (en)	2019-12-31
JP6655052B2 (en)	2020-02-26
WO2014177060A1 (en)	2014-11-06
AU2014261894B2 (en)	2018-10-18
US20160158234A1 (en)	2016-06-09
US20200171029A1 (en)	2020-06-04
US20140328805A1 (en)	2014-11-06
CR20200177A (en)	2020-06-28
TW201841907A (en)	2018-12-01
US20200188397A1 (en)	2020-06-18
IL296526B2 (en)	2025-02-01
US20180117044A1 (en)	2018-05-03
EP2991978C0 (en)	2025-08-20
US20180133219A1 (en)	2018-05-17
KR20160003241A (en)	2016-01-08
PE20161063A1 (en)	2016-10-22
US9266862B2 (en)	2016-02-23
EP2991978A1 (en)	2016-03-09
CA2911051A1 (en)	2014-11-06
BR112015027055A2 (en)	2017-07-25
PH12015502410A1 (en)	2016-02-22
US10010549B2 (en)	2018-07-03
AU2019200249A1 (en)	2019-01-31
CR20150589A (en)	2015-12-07
EA033084B1 (en)	2019-08-30
KR101836431B1 (en)	2018-03-09
PH12019502378A1 (en)	2022-05-11
MY182082A (en)	2021-01-18
MA38624A1 (en)	2017-02-28
KR102002265B1 (en)	2019-07-19
JP6229042B2 (en)	2017-11-08
TWI710558B (en)	2020-11-21
AU2014261894A1 (en)	2015-10-29
JP2018035187A (en)	2018-03-08
EA029568B1 (en)	2018-04-30
EP2991978A4 (en)	2016-09-14
US20170239246A9 (en)	2017-08-24
HK1219276A1 (en)	2017-03-31
IL296526A (en)	2022-11-01
CN110003178A (en)	2019-07-12
MX2015015130A (en)	2016-02-18
EA029568B8 (en)	2018-08-31
CN105431420B (en)	2019-08-13
CN110003178B (en)	2022-02-25
KR20180026806A (en)	2018-03-13
IL296526B1 (en)	2024-10-01
JP2020079264A (en)	2020-05-28
USRE47848E1 (en)	2020-02-11
US11129832B2 (en)	2021-09-28
UA121016C2 (en)	2020-03-25
SG11201509027WA (en)	2015-12-30

Publication	Publication Date	Title
IL274355B (en)	2021-02-28	Aza-pyridone compounds and uses thereof
SG11201509027WA (en)	2015-12-30	Biheteroaryl compounds and uses thereof
ZA201602220B (en)	2018-05-30	Heterocyclic compounds and uses thereof
IL243420A0 (en)	2016-02-29	Heterocyclic compounds and uses thereof
ZA201506434B (en)	2019-09-25	Heterocyclic compounds and uses thereof
PT2951177T (en)	2018-05-23	Imidazopyridine compounds and uses thereof
IL240788A0 (en)	2015-10-29	Heterocyclic compounds and their uses
GB201323008D0 (en)	2014-02-12	Compounds and uses thereof
GB201300707D0 (en)	2013-02-27	Compounds and processes
GB201307233D0 (en)	2013-05-29	Compounds and uses thereof
GB201320992D0 (en)	2014-01-15	Complex and uses thereof
GB201309180D0 (en)	2013-07-03	Compounds and Their Uses
PL3049517T3 (en)	2018-10-31	Hetero-transglycosylase and uses thereof
GB201314610D0 (en)	2013-10-02	Compounds and their uses
GB201306248D0 (en)	2013-05-22	Compounds and their uses
GB201323005D0 (en)	2014-02-12	Compounds and uses thereof
GB201320161D0 (en)	2014-01-01	Compounds and their uses
GB201307202D0 (en)	2013-05-29	New compounds and uses
GB201307201D0 (en)	2013-05-29	New compounds and uses
GB201301734D0 (en)	2013-03-20	New compounds and uses

Movatterモバイル変換

SG10201707002VA - Biheteroaryl compounds and uses thereof - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=51841525

Family Applications (2)

Family Applications After (1)

Country Status (22)

Families Citing this family (24)

Family Cites Families (35)

Also Published As

Similar Documents